Prot #MK3475-716: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)

Project: Research project

Project Details

StatusFinished
Effective start/end date10/25/18 → 10/25/24

Funding

  • DrugDev Inc. (Prot #MK3475-716 // Prot #MK3475-716)
  • Merck Sharp & Dohme Corporation (Prot #MK3475-716 // Prot #MK3475-716)